Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharma) today announced strategic collaboration with Cigalah Medpharm Trading LLC, a leading pharmaceutical company in the Middle East and North Africa (MENA) region, to commercialize Sebaloxavir Marboxil in the MENA market. Under the agreement, Cigalah has exclusive distribution rights of Sebaloxavir Marboxil, an innovative anti-influenza drug Zenshine Pharma has developed, in the eleven MENA countries.
“This strategic collaboration with Cigalah marks a significant milestone in Zenshine’s globalization journey." stated Dr. Jinfu Yang, Co-founder and Chairman of Zenshine Pharma, " Sebaloxavir Marboxil is an anti-influenza drug with demonstrated efficacy and safety and requires only one oral dose for the entire treatment. Cigalah's strong capabilities of commercialization will ensure the influenza patients across the MENA countries will benefit from the innovation."
"We are pleased to collaborate with Zenshine Pharma to introduce Sebaloxavir Marboxil to MENA," emphasized Ahdy Elsays, General Manager of Cigalah. "Influenza poses a significant challenge to public health safety. Sebaloxavir Marboxil has demonstrated outstanding clinical value and is already approved in China. We look forward to working closely with Zenshine Pharma to bring this innovative product to the people of the 11 MENA countries as soon as possible."
The signing of this agreement signifies the official launch of commercialization process of Sebaloxavir Marboxil in the MENA countries. The teams from both companies will collaborate closely to advance registration and market access, striving to make this innovative drug available to influenza patients in MENA at the earliest opportunity.
About Zenshine Pharma
Zenshine Pharmaceuticals is a commercialization-stage biopharmaceutical company, focused on small molecule therapeutics in the therapeutic areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine Pharmaceuticals leverages the team's extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine Pharmaceuticals commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.
About Cigalah Medpharm Trading LLC
Cigalah Medpharm Trading LLC is a leading diversified pharmaceutical and healthcare company in MENA, with businesses spanning multiple sectors including drug manufacturing, distribution, retail, and medical services. Cigalah possesses an extensive commercial network and strong marketing capabilities, and has long been committed to introducing the world's cutting-edge pharmaceutical innovations to the MENA region to enhance the region's healthcare level.
